Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
Calories: 360390 Protein: 3035g GLP-1 Tip: Soy milk adds protein without extra thickness
Saxenda (liraglutide): Once-daily injectable
But until now, they have largely been available in the U.S
We want to be transparent about where the research stands
(Read more about tryptophan, kynurenine, serotonin, and genetics.) Allergies, COVID-19, and depression and anxiety: A study of the psychological impact of COVID-19 revealed that people with allergies, which chronically raise inflammatory cytokine levels, were more likely to have PTSD and depression after COVID-19.[ref] Another study found that people with systemically elevated inflammation after COVID-19 illness were at an increased risk of depression, anxiety, or PTSD.[ref] While there is a lot of swirl and science about long-haul COVID symptoms, previous research on other viruses that remain active or reactivate (e.g., Epstein-Barr virus, cytomegalovirus) also has links between infection, inflammatory cytokines, and depression.[ref] Inflammation, Depression, and Anxiety: Genotype Report Access this content: An active subscription is required to access this content